The LAT1 inhibitor JPH203 reduced cell proliferation in resistant cells, suggesting LAT1 as a potential therapeutic target in AI-resistant breast cancer (Shindo et al., 2021). This evidence concerns the gene SLC7A5 and breast carcinoma.